stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) Return on equity
ACADIA Pharmaceuticals Inc.'s return on equity over the twelve months to 30 September 2026 was 31.4%, down 8.5 percentage points from fiscal 2025 (39.9%). Over the past ten years it has ranged from −75.6% (fiscal 2016) to 39.9% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 39.9% | 1.00 |
| FY2024 | 38.9% | 53.62 |
| FY2023 | −14.7% | 31.16 |
| FY2022 | −45.9% | (17.14) |
| FY2021 | −28.8% | 13.72 |
| FY2020 | −42.5% | (2.54) |
| FY2019 | −39.9% | 20.29 |
| FY2018 | −60.2% | 7.58 |
| FY2017 | −67.8% | 7.78 |
| FY2016 | −75.6% | (11.00) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. | 31.4% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| TNGX Tango Therapeutics, Inc. compare | −21.3% |
| IOVA Iovance Biotherapeutics, Inc. compare | −29.1% |
| RLAY Relay Therapeutics, Inc. compare | −36.8% |
| IRON Disc Medicine, Inc. compare | −39.1% |
| XENE Xenon Pharmaceuticals Inc. compare | −43.6% |
| DYN Dyne Therapeutics, Inc. compare | −81.6% |
| VKTX Viking Therapeutics, Inc. compare | −96.4% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ACAD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement